CA2310294C - Composition et methode pour prevenir ou traiter le cancer du sein - Google Patents

Composition et methode pour prevenir ou traiter le cancer du sein Download PDF

Info

Publication number
CA2310294C
CA2310294C CA002310294A CA2310294A CA2310294C CA 2310294 C CA2310294 C CA 2310294C CA 002310294 A CA002310294 A CA 002310294A CA 2310294 A CA2310294 A CA 2310294A CA 2310294 C CA2310294 C CA 2310294C
Authority
CA
Canada
Prior art keywords
isoflavone
tamoxifen
composition
breast cancer
minimize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002310294A
Other languages
English (en)
Other versions
CA2310294A1 (fr
Inventor
E. C. Henley
Richard B. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solae LLC
Original Assignee
Protein Technologies International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Technologies International Inc filed Critical Protein Technologies International Inc
Priority to CA002310294A priority Critical patent/CA2310294C/fr
Publication of CA2310294A1 publication Critical patent/CA2310294A1/fr
Application granted granted Critical
Publication of CA2310294C publication Critical patent/CA2310294C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002310294A 2000-05-30 2000-05-30 Composition et methode pour prevenir ou traiter le cancer du sein Expired - Fee Related CA2310294C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002310294A CA2310294C (fr) 2000-05-30 2000-05-30 Composition et methode pour prevenir ou traiter le cancer du sein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002310294A CA2310294C (fr) 2000-05-30 2000-05-30 Composition et methode pour prevenir ou traiter le cancer du sein

Publications (2)

Publication Number Publication Date
CA2310294A1 CA2310294A1 (fr) 2001-11-30
CA2310294C true CA2310294C (fr) 2005-02-08

Family

ID=4166342

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002310294A Expired - Fee Related CA2310294C (fr) 2000-05-30 2000-05-30 Composition et methode pour prevenir ou traiter le cancer du sein

Country Status (1)

Country Link
CA (1) CA2310294C (fr)

Also Published As

Publication number Publication date
CA2310294A1 (fr) 2001-11-30

Similar Documents

Publication Publication Date Title
CA2308530C (fr) Methode pour prevenir ou reduire le risque de degenerescence maculaire
CA2306008C (fr) Composition et methode pour reduire la concentration du cholesterol lipoproteine a faible densite
US6251400B1 (en) Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
JPH11139973A (ja) 血中のｌｄｌ−コレステロール濃度を減少しｈｄｌ−コレステロール濃度を増加させ、アテローム硬化症及び道管病の危険性を減少させる方法
US6326366B1 (en) Hormone replacement therapy
US20040116498A1 (en) Regulations of lipids and/or bone density and compositions therefor
AU2002227771A1 (en) Regulation of lipids and/or bone density and compositions therefor
JPH0543469A (ja) β−グルクロニダーゼ阻害剤
US6300367B1 (en) Composition for and method of preventing or treating breast cancer
US7285297B1 (en) Method of reducing low density liproprotein cholesterol concentration
JPH08231533A (ja) 新規フラボノイド配糖体およびフラボノイド配糖体を含む骨粗鬆症治療剤ならびに可食性組成物
EP1159963A1 (fr) Composition et procédé pour la prévention et le traitement du cancer du sein
AU4879400A (en) Composition for and method of preventing or treating breast cancer
CA2310290C (fr) Composition et methode pour prevenir ou traiter le cancer du sein
KR20010108719A (ko) 유방암의 예방 또는 치료용 조성물 및 그 예방 또는 치료방법
JP2001335484A (ja) 乳癌を予防又は治療するための組成物又はその方法
KR20010111912A (ko) 유방암의 예방 또는 치료용 조성물 및 방법
JP2001342132A (ja) 乳癌を予防し、もしくは治療するための組成物およびそのための方法
MXPA00005292A (es) Composicion y metodo de prevencion o tratamiento de cancer de mama.
CN1335133A (zh) 预防或治疗乳腺癌的组合物和方法
AU4086900A (en) Composition for and method of preventing or treating breast cancer
MXPA00006034A (en) Composition, prevention method or treatment for breast cancer
JP2001253823A (ja) Ｈｉｖ遺伝子発現抑制剤
AU783838B2 (en) Composition for and method of reducing low density lipoprotein cholesterol concentration
CN1335134A (zh) 预防或治疗乳腺癌的组合物和方法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed